Evaluate VOD Risk
Proactively Manage VOD
Note: Due to the small sample size, results should be interpreted with caution.
Additionally, some patients may not have developed VOD at the time of this analysis.4
Variable tested | Odds ratio | |||
---|---|---|---|---|
Multivariate analysis | ||||
Conditioning regimens containing dual alkylators | 8.61 P= 0.015 |
|||
Bilirubin levels ≥ ULN at last measurement before conditioning therapy | 7.08 P = 0.011 |
|||
Bilirubin levels ≥ ULN at last measurement before follow-up HSCT | 15.31 P = 0.009 |
|||
Prior HSCT | 6.02 P = 0.032 |
|||
Univariate analysisa | ||||
Age ≥ 55 years | 3.25 2-sided P = 0.048 |
|||
Number of treatment cycles received |
1.56
2-sided P = 0.048
|
Short overview showing post HSCT survival outcomes with BESPONSA from INO-VATE long term follow-up and pooled analysis
Click here to view the key data from publication entitled, “Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database”
Explore BESPONSA outcomes and safety in RWE
EBMT diagnostic, prevention and treatment recommendations, please also view the BESPONSA SmPC here
Short overview showing post HSCT survival outcomes with BESPONSA from INO-VATE long term follow-up and pooled analysis
Click here to view the key data from publication entitled, “Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database”
Explore BESPONSA outcomes and safety in RWE
Example
Please click here to view the importance of transplant and VOD mitigation with BESPONSA in patients with R/R B-Cell ALL
Legal Category: S1A
Further information is available upon request
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023